This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

aaiPharma Slammed on Earnings

Updated from 8:36 a.m. EDT

Shares of aaiPharma (AAII) fell Tuesday following the company's announcement late Monday that second-quarter earnings rose while revenue fell in comparison to the same period last year.

The stock dropped 28 cents, or 8.3%, to $3.11 in morning trading.

The higher profit and the lower revenue were both due primarily to the company's sale of its injectable vitamin businesses on April 26. The company recorded a net gain of $37.5 million for the three months ended June 30.

The Wilmington, N.C.-based drug company, which announced its financial results Monday after markets had closed, earned $7.2 million, or 25 cents a share, on sales of $51.5 million for the second quarter of 2004.

For the same period last year, the company earned $3.5 million, or 12 cents a share, on revenue of $66.1 million.

The lower revenue for 2004's second quarter also was caused by lower sales among several products due to high inventories of those goods still being held by distributors. Higher expenses for the second quarter were caused, in part, by a dispute between aaiPharma and another drug company and by an investigation by board members into the reasons for the excessive inventories and the accounting problems linked to the inventories.

The company is "still clearing the decks in rough seas," said David W. Maris, of Banc of America Securities, in a research report issued Tuesday just before aaiPharma conducted a telephone conference call for investors and analysts.

Excluding the gain on the vitamin businesses' sale, aaiPharma lost 54 cents a share for this year's second quarter, Maris said. The consensus view of two analysts polled by Thomson First Call was a loss of 20 cents a share.

The company still has a long way to go to regain the confidence of investors and analysts; and it still must resuscitate its stock price, which hit a 52-week high of $31.85 on Jan. 21 and has dropped steadily since then. According to Thomson First Call, three analysts recommend holding aaiPharma's stock, while three analysts advocate selling it.

"Despite being a long way from returning to profitability, the company's principal focus may be liquidity," said Maris, who has a neutral rating on a stock that he calls extremely volatile.

Maris said aaiPharma still suffers from uncomfortably high levels of products still sitting in distributors' warehouses, "which restricts cash flow regardless of end-user demand." (He doesn't own shares; his firm has had an investment banking relationship with aaiPharma). Maris added that the company has made progress in reducing inventory levels.

Cutting inventory was one theme emphasized by Frederick D. Sancilio, aaiPharma's chairman and CEO, during the Tuesday telephone conference call with investors. He added that executives will complete a strategic review of the company during the third quarter, enabling aaiPharma to give Wall Street a clearer picture of the company's plans. Part of that strategy includes redirecting the sales efforts away from retail outlets and back to hospitals and pain clinics in an effort to return aaiPharma "to normal operations in 2005," Sancilio said. The revised sales activities already have begun, he said.

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,778.15 +421.28 2.43%
S&P 500 2,061.23 +48.34 2.40%
NASDAQ 4,748.3960 +104.0840 2.24%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs